Drug Science launched Europe’s first and biggest national medical cannabis registry, called Project Twenty21, on the 7th November 2019.
Project TWENTY21 aims to enrol 20,000 patients by the end of 2021, creating the largest body of evidence for the effectiveness and tolerability of medical cannabis – with an aim to demonstrate to policymakers that medical cannabis should be as widely available, and affordable, as other approved medicines for patients who would benefit from them.
TWENTY21 is a registry, not a clinical trial.
It will also support prescribers across the country to feel confident in providing medical cannabis to patients. We hope that the findings will make a powerful case for NHS funding, by proving the favourable risk/benefit ratio of medical cannabis in seven key identified conditions. In the first instance, this real-world registry will be targeting the following patients and situations:
- Anxiety Disorder
- Chronic Pain
- Multiple Sclerosis (MS)
- Post Traumatic Stress Disorder (PTSD)
- Substance Use Disorder (as a harm reduction strategy)
- Tourette’s Syndrome
*Although Project Twenty21 aims to collect health outcome measures in cases of intractable epilepsy, for reasons outside of Drug Science’s control, we have been unable to subsidise the cost of medication for this condition. We are working hard to find a solution for this and will keep patients updated. In the interim, if patients wish to seek Cannabis-Based Medicinal Products for this condition, they can receive treatment at a private medical cannabis clinic, but this will be outside the scope of Twenty21 subsidised costing, at this time.
Furthermore, medical cannabis clinics will only accept patients who have attempted two different licensed medications to treat their condition, both of which must have proven to be ineffective.
Treatment will be provided at a network of clinics across the UK and remotely through telemedicine services, both of which utilise best-practice in medical cannabis treatment from recognised global leaders in medical cannabis, including Canada and Australia.
If you are patient with one (or more) of the conditions named above, and wish to hear more about Project Twenty21, please submit your name and email address below.
PLEASE NOTE: Prescription of medical cannabis will remain the decision of the provider, dependent on full clinical assessment and physician recommendation. Drug Science takes no responsibility for clinical oversight.
If you are a GMC registered consultant psychiatrist, neurologist or pain specialist and are interested in contributing to Project Twenty21 data collection when prescribing medical cannabis to your patients, please email firstname.lastname@example.org. The primary objective of Project Twenty21 is to develop a body of evidence using a real-world data (RWD) registry to document efficacy, safety, QALY, and patient reported outcomes with regards to medical cannabis use.